CVACÂ – CureVac N.V.
CureVac N.V.CVAC
$5.43Name : CureVac N.V.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,222,688,000.00
EPSttm : 1.01
CureVac N.V.
$5.43
0.37%$0.02Float Short %
1.23
Margin Of Safety %
2
Put/Call OI Ratio
0.45
EPS Next Q Diff
0.23
EPS Last/This Y
-1.5
EPS This/Next Y
0.16
Price
5.43
Target Price
5.47
Analyst Recom
3
Performance Q
-1.27
Relative Volume
0.65
Beta
2.56
Ticker: CVAC
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | CVAC | 5.36 | 0.32 | 0.10 | 4372 |
| 2025-09-09 | CVAC | 5.38 | 0.32 | 0.00 | 4374 |
| 2025-09-10 | CVAC | 5.38 | 0.32 | 0.00 | 4364 |
| 2025-09-11 | CVAC | 5.39 | 0.33 | 0.00 | 4246 |
| 2025-09-12 | CVAC | 5.34 | 0.33 | 0.00 | 4220 |
| 2025-09-15 | CVAC | 5.38 | 0.34 | 0.00 | 4160 |
| 2025-09-16 | CVAC | 5.36 | 0.34 | 0.00 | 4172 |
| 2025-09-17 | CVAC | 5.36 | 0.33546121927865 | 0.016949152542373 | 4184 |
| 2025-09-18 | CVAC | 5.36 | 0.33 | 0.00 | 4202 |
| 2025-09-22 | CVAC | 5.37 | 0.35 | 2.07 | 4022 |
| 2025-09-23 | CVAC | 5.38 | 0.42 | 0.00 | 4292 |
| 2025-09-24 | CVAC | 5.36 | 0.42 | 0.00 | 4302 |
| 2025-09-25 | CVAC | 5.35 | 0.42 | 0.09 | 4307 |
| 2025-09-26 | CVAC | 5.36 | 0.43 | 0.00 | 4284 |
| 2025-09-29 | CVAC | 5.36 | 0.43 | 0.00 | 4286 |
| 2025-09-30 | CVAC | 5.39 | 0.43 | 0.00 | 4278 |
| 2025-10-01 | CVAC | 5.4 | 0.43 | 0.00 | 4278 |
| 2025-10-02 | CVAC | 5.4 | 0.43 | 0.50 | 4281 |
| 2025-10-03 | CVAC | 5.45 | 0.43 | 0.00 | 4282 |
| 2025-10-06 | CVAC | 5.41 | 0.45 | 0.00 | 4134 |
| 2025-10-07 | CVAC | 5.43 | 0.45 | 0.00 | 4134 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | CVAC | 5.35 | -110.0 | -333.1 | -0.49 |
| 2025-09-09 | CVAC | 5.38 | -110.0 | -334.8 | -0.66 |
| 2025-09-10 | CVAC | 5.38 | -110.0 | -334.5 | -0.66 |
| 2025-09-11 | CVAC | 5.39 | -110.0 | -334.4 | -0.66 |
| 2025-09-12 | CVAC | 5.34 | -110.0 | -333.1 | -0.66 |
| 2025-09-15 | CVAC | 5.37 | -110.0 | -335.0 | -0.66 |
| 2025-09-16 | CVAC | 5.35 | -110.0 | -334.1 | -0.66 |
| 2025-09-17 | CVAC | 5.37 | -110.0 | -334.9 | -0.66 |
| 2025-09-18 | CVAC | 5.36 | -110.0 | -334.7 | -0.66 |
| 2025-09-19 | CVAC | 5.36 | -110.0 | -334.3 | -0.66 |
| 2025-09-22 | CVAC | 5.36 | -110.0 | -334.3 | -0.66 |
| 2025-09-23 | CVAC | 5.37 | -110.0 | -334.1 | -0.66 |
| 2025-09-24 | CVAC | 5.36 | -110.0 | -334.3 | -0.66 |
| 2025-09-25 | CVAC | 5.35 | -110.0 | -334.1 | -0.66 |
| 2025-09-26 | CVAC | 5.37 | -110.0 | -334.5 | -0.66 |
| 2025-09-29 | CVAC | 5.36 | -110.0 | -333.6 | -0.66 |
| 2025-09-30 | CVAC | 5.39 | -110.0 | -334.9 | -0.66 |
| 2025-10-01 | CVAC | 5.40 | -110.0 | -334.3 | -0.66 |
| 2025-10-02 | CVAC | 5.40 | -110.0 | -334.0 | -0.66 |
| 2025-10-03 | CVAC | 5.45 | -110.0 | -335.4 | -0.66 |
| 2025-10-06 | CVAC | 5.42 | -110.0 | -337.6 | -0.66 |
| 2025-10-07 | CVAC | 5.43 | -110.0 | -337.4 | -0.66 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | CVAC | 0.00 | 10.41 | 0.70 |
| 2025-09-09 | CVAC | 0.00 | 10.41 | 0.70 |
| 2025-09-10 | CVAC | 0.00 | 10.41 | 0.70 |
| 2025-09-11 | CVAC | 0.00 | 10.41 | 0.89 |
| 2025-09-12 | CVAC | 0.00 | 10.41 | 0.89 |
| 2025-09-15 | CVAC | 0.00 | 10.42 | 0.89 |
| 2025-09-16 | CVAC | 0.00 | 10.42 | 0.89 |
| 2025-09-17 | CVAC | 0.00 | 10.42 | 0.89 |
| 2025-09-18 | CVAC | 0.00 | 10.42 | 0.89 |
| 2025-09-19 | CVAC | 0.00 | 10.42 | 0.89 |
| 2025-09-22 | CVAC | 0.00 | 10.42 | 0.89 |
| 2025-09-23 | CVAC | 0.00 | 10.42 | 0.89 |
| 2025-09-24 | CVAC | 0.00 | 10.42 | 0.89 |
| 2025-09-25 | CVAC | 0.00 | 10.42 | 1.23 |
| 2025-09-26 | CVAC | 0.00 | 10.42 | 1.23 |
| 2025-09-29 | CVAC | 0.00 | 10.42 | 1.23 |
| 2025-09-30 | CVAC | 0.00 | 10.42 | 1.23 |
| 2025-10-01 | CVAC | 0.00 | 10.42 | 1.23 |
| 2025-10-02 | CVAC | 0.00 | 10.42 | 1.23 |
| 2025-10-03 | CVAC | 0.00 | 10.42 | 1.23 |
| 2025-10-06 | CVAC | 0.00 | 2.34 | 1.23 |
| 2025-10-07 | CVAC | 0.00 | 2.34 | 1.23 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS​
-0.3
Avg. EPS Est. Current Quarter
-0.15
Avg. EPS Est. Next Quarter
-0.07
Insider Transactions
Institutional Transactions
2.34
Beta
2.56
Average Sales Estimate Current Quarter
34
Average Sales Estimate Next Quarter
32
Fair Value
5.56
Quality Score
100
Growth Score
59
Sentiment Score
80
Actual DrawDown %
96.4
Max Drawdown 5-Year %
-98.3
Target Price
5.47
P/E
6.02
Forward P/E
PEG
P/S
2.13
P/B
1.75
P/Free Cash Flow
7.66
EPS
0.9
Average EPS Est. Cur. Y​
-0.66
EPS Next Y. (Est.)
-0.49
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
35.42
Relative Volume
0.65
Return on Equity vs Sector %
7.8
Return on Equity vs Industry %
21.5
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.17
EBIT Estimation
-337.4
CureVac N.V.Sector: Healthcare
Industry: Biotechnology
Employees: 825
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in TĂĽbingen, Germany.
stock quote shares CVACÂ – CureVac N.V. Stock Price stock today
news today CVACÂ – CureVac N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch CVACÂ – CureVac N.V. yahoo finance google finance
stock history CVACÂ – CureVac N.V. invest stock market
stock prices CVAC premarket after hours
ticker CVAC fair value insiders trading